San Jose, California (PRWEB) June 03, 2014
Follow us on LinkedIn – Fueled by the importance of accurate and sensitive diagnosis offered by proteomics in the area of personalized medicine, the market for proteomics is expected to register strong growth in the coming years. Detailed analysis of proteins provides better opportunities for the development of drugs that can target disease pathways more efficiently. The discovery of new protein biomarkers in disease development, and the corresponding development of novel drugs for cancer, cardiovascular, and neurodegenerative diseases have strengthened the market in recent years. Identification and characterization of proteins provides a deeper understanding of disease mechanisms when compared to genetic profiling. Funding support offered by government and private organizations for proteomics research, developments in mass spectrometry-based proteomic and chemoproteomic strategies, and increased focus of biotechnology and pharmaceutical companies on novel drug discovery methods, bode well for the global proteomics market. Despite the opportunities for growth, the market will continue to face challenges such as tough regulatory approvals, dearth of qualified and skilled research manpower, and high cost of proteomics instruments and equipment.
As stated by the new market research report on Proteomics, the United States represents the largest market worldwide, followed by Europe. Emerging economies of Asia and Latin America are poised to fuel future growth in the market supported by socioeconomic growth, increased focus on biotechnological research, strong government support, and increased outsourcing of proteomics services to Asian countries.
Over the next decade, better understanding of proteome will lead to the development of advanced sequencing methods and superior technologies that help expand application possibilities. Discovery of new biomarkers is expected to enable successful development of newer drugs. Technological improvements in instruments and workflow and miniaturization of biochip devices will create new milestones in diagnosis and drug development applications. Biomarker-based research will be a strong area of focus given the increasing importance of proteomics in novel drug discovery, design, and development. Recently developed biomarker-discovery platforms include relative quantitative proteomic tools, such as the iTRAQ (isobaric Tagging for Relative and Absolute Quantitation) and SILAC (Stable Isotope Labeling by Amino Acids in Cell Culture).
Major players covered in the report include Bio-Rad Laboratories Inc., ThermoFisher Scientific, Waters Corporation, Sigma-Aldrich Corporation, PerkinElmer Inc., Bruker Daltonics Inc., Caprion Proteomics Inc., GE Healthcare, and Shimadzu Biotech, among others.
The research report titled “Proteomics: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, growth drivers, challenges and issues, mergers and acquisitions, and other strategic industry activities of major global and niche companies. The report provides market estimates and projections for all major geographic markets, such as the United States, Canada, Japan, Europe (France, Germany, Italy, UK, and the Rest of Europe), Asia-Pacific, Latin America, and Rest of World.
For more details about this comprehensive market research report, please visit: http://www.strategyr.com/Proteomics_Market_Report.asp.
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes 1500+ full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.
Global Industry Analysts, Inc.
Web Site: http://www.StrategyR.com/